Literature DB >> 24445941

[Persistent and recurrent skin and soft tissue infections by Staphylococcus aureus. Impact of the small colony-variant (SCV) phenotype and of Panton-Valentine leukocidin (PVL)-positive S. aureus isolates].

K Becker1, A Kriegeskorte, C Sunderkötter, B Löffler, C von Eiff.   

Abstract

Staphylococcus aureus is one of the major pathogens causing chronic skin and soft tissue infections. Particularly isolates producing Panton-Valentine leukocidin (PVL) comprising methicillin-susceptible and community-associated methicillin-resistant S. aureus (CA-MRSA) have been associated with more aggressive and persistent or relapsing courses. Beyond classical resistance mechanisms, functional resistance as shown by the small colony-variant (SCV) phenotype could be also responsible for treatment failures, despite the administration of antibiotics tested in vitro as susceptible. Also this phenotype has been associated with chronic courses of infections often with multiple exacerbations. Due to their ability to persist intracellularly, SCVs are protected from host defense and antibiotic treatment if only extracellularly active agents are administered. Reduced growth, abnormal colony morphology and changes in the metabolism of the SCVs aggravate drastically their identification, differentiation and susceptibility testing. The diagnostic and therapeutic challenges of PVL-positive and SCV isolates necessitate close collaboration with microbiological and infectious disease specialists.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24445941     DOI: 10.1007/s00105-013-2636-8

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  64 in total

Review 1.  Small-colony variants (SCVs) of staphylococci: a role in foreign body-associated infections.

Authors:  C von Eiff; K Becker
Journal:  Int J Artif Organs       Date:  2007-09       Impact factor: 1.595

2.  Evaluation of two chromogenic agar media for recovery and identification of Staphylococcus aureus small-colony variants.

Authors:  Frank Kipp; Barbara C Kahl; Karsten Becker; Ellen J Baron; Richard A Proctor; Georg Peters; Christof von Eiff
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

3.  Biological and ecological investigations on thiamineless dwarf-colony variants of Staphylococcus aureus of bovine udder origin.

Authors:  G Ziv; D Sompolinsky
Journal:  Res Vet Sci       Date:  1976-05       Impact factor: 2.534

4.  Human beta-defensin 3 inhibits cell wall biosynthesis in Staphylococci.

Authors:  Vera Sass; Tanja Schneider; Miriam Wilmes; Christian Körner; Alessandro Tossi; Natalia Novikova; Olga Shamova; Hans-Georg Sahl
Journal:  Infect Immun       Date:  2010-04-12       Impact factor: 3.441

5.  Staphylococcus aureus Panton-Valentine leukocidin induces an inflammatory response in human phagocytes via the NLRP3 inflammasome.

Authors:  Dirk Holzinger; Laura Gieldon; Vijayashree Mysore; Nadine Nippe; Debra J Taxman; Joseph A Duncan; Peter M Broglie; Kristina Marketon; Judith Austermann; Thomas Vogl; Dirk Foell; Silke Niemann; Georg Peters; Johannes Roth; Bettina Löffler
Journal:  J Leukoc Biol       Date:  2012-08-14       Impact factor: 4.962

6.  Development and evaluation of a quality-controlled ribosomal sequence database for 16S ribosomal DNA-based identification of Staphylococcus species.

Authors:  Karsten Becker; Dag Harmsen; Alexander Mellmann; Christian Meier; Peter Schumann; Georg Peters; Christof von Eiff
Journal:  J Clin Microbiol       Date:  2004-11       Impact factor: 5.948

7.  Intracellular persistence of Staphylococcus aureus small-colony variants within keratinocytes: a cause for antibiotic treatment failure in a patient with darier's disease.

Authors:  C von Eiff; K Becker; D Metze; G Lubritz; J Hockmann; T Schwarz; G Peters
Journal:  Clin Infect Dis       Date:  2001-04-30       Impact factor: 9.079

8.  Staphylococcus aureus small-colony variants are adapted phenotypes for intracellular persistence.

Authors:  Lorena Tuchscherr; Vanessa Heitmann; Muzaffar Hussain; Dorothee Viemann; Johannes Roth; Christof von Eiff; Georg Peters; Karsten Becker; Bettina Löffler
Journal:  J Infect Dis       Date:  2010-10-01       Impact factor: 5.226

9.  Staphylococcal Panton-Valentine leukocidin induces pro-inflammatory cytokine production and nuclear factor-kappa B activation in neutrophils.

Authors:  Xiaoling Ma; Wenjiao Chang; Cuiping Zhang; Xin Zhou; Fangyou Yu
Journal:  PLoS One       Date:  2012-04-18       Impact factor: 3.240

10.  Staphylococcus aureus panton-valentine leukocidin is a very potent cytotoxic factor for human neutrophils.

Authors:  Bettina Löffler; Muzaffar Hussain; Matthias Grundmeier; Michaela Brück; Dirk Holzinger; Georg Varga; Johannes Roth; Barbara C Kahl; Richard A Proctor; Georg Peters
Journal:  PLoS Pathog       Date:  2010-01-08       Impact factor: 6.823

View more
  5 in total

Review 1.  [Systemic therapy with antibiotics. Overview of important antibiotics in dermatology].

Authors:  C Sunderkötter; K Becker
Journal:  Hautarzt       Date:  2014-02       Impact factor: 0.751

2.  [Soft tissue infections].

Authors:  Robert Rongisch; Mario Fabri
Journal:  Hautarzt       Date:  2022-01-27       Impact factor: 0.751

Review 3.  Fracture-related infection.

Authors:  T Fintan Moriarty; Willem-Jan Metsemakers; Mario Morgenstern; Marloes I Hofstee; Alejandro Vallejo Diaz; James E Cassat; Britt Wildemann; Melissa Depypere; Edward M Schwarz; R Geoff Richards
Journal:  Nat Rev Dis Primers       Date:  2022-10-20       Impact factor: 65.038

Review 4.  [Systemic therapy with anti-infective agents. Principles of rational use of systemic antibiotics in dermatology].

Authors:  C Sunderkötter; R Brehler; K Becker
Journal:  Hautarzt       Date:  2014-02       Impact factor: 0.751

5.  The msaABCR Operon Regulates Persister Formation by Modulating Energy Metabolism in Staphylococcus aureus.

Authors:  Shanti Pandey; Gyan S Sahukhal; Mohamed O Elasri
Journal:  Front Microbiol       Date:  2021-04-14       Impact factor: 5.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.